Revolution Medicines 株価情報 (NASDAQ: RVMD)

Revolution Medicines (NASDAQ:RVMD) 株価情報

Revolution Medicines

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Revolution Medicines, Inc. - Common Stock

Revolution Medicines Inc

Scaled Investment Platform Expands Apollo's Origination Capabilities in Residential and Industrial Real Estate
Bridge Manages $50 Billion of High-Quality AUM in Complementary Sectors Aligned with Apollo's Long-Term Growth Strategy
NEW YORK and SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Apollo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) and Bridge Investment Group Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRDG#NYSE">BRDG</a>) ("Bridge" or the "Company") today announced they have entered into a definitive agreement for Apollo to acquire Bridge in an all-stock transaction with an equity value of approximately $1.5 billion.

News

Asset Sales

BRDG

Apollo Has Entered Into A Definitive Agreement To Acquire Bridge In An All-Stock Transaction With An Equity Value Of ~$1.5B

reAlpha Tech Corp. ("reAlpha") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>), a real estate technology company developing and commercializing artificial intelligence ("AI") technologies, today announced the acquisition of GTG Financial, Inc. ("GTG Financial"), a mortgage brokerage company founded by Glenn Groves, a U.S. Marine and industry leader. GTG Financial is licensed to operate in seven U.S. states, including California, which will expand reAlpha's geographic footprint to a total of 28 U.S. states and strengthen its operational capacity.

AIRE

reAlpha Acquires GTG Financial, Inc.; No Financial Terms Disclosed

Celularity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) ("Celularity" or the "Company"), a cellular and regenerative medicine company, today announced that it has entered into a Master Services Collaboration Agreement with BlueSphere Bio, Inc. (BSB) covering manufacturing activities for certain BSB cell therapy products. This collaboration is the second of its kind for Celularity and demonstrates the Company's ability to leverage its world class cGMP manufacturing infrastructure and deep expertise to attract clients like BSB, who are seeking differentiated alternatives to manufacture their therapeutic products in an ever-changing landscape. This collaboration further evidences the revenue generating potential of Celularity's assets.
The Collaboration Agreement will initially focus on the production of BSB's novel T cell receptor (TCR) T cell therapies using the technical and manufacturing capabilities at Celularity's Florham Park, NJ, cGMP-ready facility. This collaboration will extend to all aspects of cell therapy manufacturing including Chemistry, Manufacturing and Controls (CMC), Quality Assurance and Quality Control. As part of this Collaboration, Celularity will dedicate staff and a small portion of its 37,000 square foot commercial manufacturing footprint. In coordination with&nbsp;Celularity management,&nbsp;BSB and its team will have oversight over production of its second cell therapy product for the treatment of Acute Myelogenous Leukemia (AML) both in the U.S. and abroad.

Biotech

General

CELU

elularity Announces Master Services Collaboration With BlueSphere Bio For Manufacturing BSB Cell Therapy Products, Utilizing Florham Park cGMP Facility; Project Involves 37K Sq Ft Space, Focus On TCR T Cell Therapy For AML

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">51.1400</td>
<td align="right">0.390</td>
<td align="right">0.76</td>
<td>253.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">91.4468</td>
<td align="right">0.517</td>
<td align="right">0.56</td>
<td>4.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">88.5000</td>
<td align="right">0.430</td>
<td align="right">0.48</td>
<td>336</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">135.4200</td>
<td align="right">0.580</td>
<td align="right">0.43</td>
<td>1.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">80.6200</td>
<td align="right">0.350</td>
<td align="right">0.43</td>
<td>1.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">147.0600</td>
<td align="right">0.630</td>
<td align="right">0.43</td>
<td>2.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">235.8400</td>
<td align="right">0.970</td>
<td align="right">0.41</td>
<td>7.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">219.0300</td>
<td align="right">0.640</td>
<td align="right">0.29</td>
<td>2.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">82.3800</td>
<td align="right">0.200</td>
<td align="right">0.24</td>
<td>9.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">42.2900</td>
<td align="right">0.060</td>
<td align="right">0.14</td>
<td>933</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">103.1300</td>
<td align="right">0.110</td>
<td align="right">0.10</td>
<td>282</td>
</tr>
</tbody>
</table>
No loser in today's Pre-market session. 
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> the above sector movers alert assists traders in understanding macro-level trends and market variations. Traders will look for sector movers providing information on sectors that are over- or under-performing, deriving these results into investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For February 24, 2025

<a href="https://www.sec.gov/Archives/edgar/data/1713210/000149315225007977/ex99-1.htm" title="https://www.sec.gov/Archives/edgar/data/1713210/000149315225007977/ex99-1.htm">https://www.sec.gov/Archives/edgar/data/1713210/000149315225007977/ex99-1.htm</a>

ATPC

AGAPE ATP Corp. Signs ICPO With Swiss One Oil & Gas AG For 200,000 MT Of EN590 And 2M Barrels Of Jet Fuel A1

Offerings

LFMD

LifeMD Expands Into the Behavioral Health Market. The Move Broadens LifeMD's Service Offerings To Include Teletherapy, Psychiatry And Medication Management For Common Mental Health Conditions.

Rezolve Ai&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>), the trailblazer in AI-driven commerce solutions, today unveiled a&nbsp;bold&nbsp;$1 billion Bitcoin treasury programme, kickstarting with an initial&nbsp;$100 million investment. This visionary move underscores Rezolve Ai's unwavering commitment to revolutionizing global commerce by seamlessly integrating artificial intelligence, blockchain technology, and cryptocurrency.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

RZLV

Rezolve Ai Launches $1B Bitcoin Treasury To Fuel The Future Of AI-Powered Crypto Commerce, Kickstarting With An Initial $100M Investment

This is the 13th patent granted out of a portfolio of 23 patents and covers SaverOne's innovative methodologies for limiting mobile phone use while driving
Petah Tikvah, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- SaverOne 2014 Ltd. (NASDAQ:<a href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>, TASE: SVRE)), a technology company engaged in developing transportation safety solutions, is pleased to announce the award by the United States Patent and Trademark Office (USPTO) of a new patent. The patent, bearing the number 12,231,899 and issued on February 18, 2025, is entitled "System and method for managing access to software applications on a mobile communication device via a phone location unit."

SVRE

SaverOne Granted New Patent In The U.S. Entitled "System And Method For Managing Access To Software Applications On A Mobile Communication Device Via A Phone Location Unit."

ARQT

Arcutis Announces Results For ZORYVE Cream In Phase 3 Trial For Pediatric Atopic Dermatitis, Meeting Primary Endpoint With 75% EASI Improvement; Itch Relief Seen In 24 Hours

The Company expects to begin 2025 with over 14,800 students, an increase of 15% over 2024.&nbsp;
While the Company anticipates overall student start growth throughout 2025, there is a planned timing shift in student starts in 2025 compared to 2024 due to a June start date shifting to July in the Company's standardized Lincoln 10.0 start calendar.&nbsp;
As a result of this start date move approximately 2,300 student starts are expected to shift from the second quarter to the third quarter. This shift is not expected to have a material impact on revenue between quarters.

Guidance

LINC

Lincoln Educational Services Expects 2025 Revenue Of $480M - $490M, Est $468.93M

Data confirms Versamune&#xAE; HPV has potential as a broadly effective treatment of HPV16-associated cancers –&nbsp;Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025
Versamune&#xAE; HPV + CRT was associated with greater and earlier clearance of blood-circulating HPV16-positive cancer cells (circulating tumor DNA/ctDNA) vs. CRT alone
100% of patients with locally advanced HPV16 cervical cancer treated with Versamune&#xAE; HPV + CRT had no detectable HPV16 ctDNA at 3-4 months vs. 50% of patients on standard-of-care CRT
Undetectable HPV ctDNA at 3-4 months was associated with improved 2-year recurrence-free survival (RFS) of 93% vs only 30% in patients with detectable HPV ctDNA
PRINCETON, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the publication of circulating tumor DNA (ctDNA) results for its lead immunotherapy candidate, Versamune&#xAE; HPV, in <a href="https://www.globenewswire.com/Tracker?data=7s_lRXMs5dIRjelaXYS7x9fJYI8SLHGAwW4GUEwyY1g5BxFiKxjn2d9dRZXhEH2fe-mODvXI6oqtPPkA2531dRrbulwWZSAe7L0eo9gbngl5j6mE2ZwzQrE_8dnDOnIXDrwSqUIj0F0VMyIGkD4_bD_sYNTMJ_apJWsNWp4K68M6c4VUHhO0zBRYcze8qZFdhj9tAfegxFOvgFnDYyGFcgnrYmMQEj7ZXniqDbicvIr4p4MQhANI8RQ6OgSMCITO4Bx7ogR0q2mLA9BSnFyEce80sGWKkWoIdv4WwFjGmyY=">Clinical Cancer Research</a>, a journal of the American Association for Cancer Research.
The trial demonstrated that Versamune&#xAE; HPV was associated with greater and earlier clearance of HPV16-positive cancer cells from the bloodstream in patients with locally advanced cervical cancer. Notably, the elimination of HPV16-positive ctDNA correlated with extended patient survival without cancer recurrence, reinforcing its potential to improve long-term outcomes. The data underscore the potential of Versamune&#xAE; HPV in HPV16-positive cancers as the Company prepares to initiate a Phase 3 clinical trial for Versamune&#xAE; HPV in HPV16-positive head and neck squamous cell carcinoma (HNSCC) in the first quarter of this year.

PDSB

PDS Biotech Announces Circulating Tumor DNA Results For Versamune HPV In IMMUNOCERV Trial Published In Clinical Cancer Research; 100% Of Patients With Locally Advanced HPV16 Cervical Cancer Treated With Versamune HPV+ CRT Had No Detectable HPV16 ctDNA At 3-4 Months Vs. 50% Of Patients On Standard-Of-care CRT

ALLR

Allarity Therapeutics Announces New Protocol for Phase 2 Trial Of Stenoparib In Ovarian Cancer; Critical Data Expected by End of Summer 2026

JP Morgan analyst Domingos Falavina maintains Nu Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>) with a Neutral and lowers the price target from $15 to $14.

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on Nu Holdings, Lowers Price Target to $14

The program will demonstrate Rocket Lab's tactically responsive space capabilities using the Company's end-to-end solutions for spacecraft design, production, launch, and operations.
Rocket Lab National Security LLC, a wholly owned subsidiary of Rocket Lab USA, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) ("Rocket Lab" or "the Company"), a global leader in launch services and space systems, today announced the successful completion of its Critical Design Review (CDR) for the U.S. Space Force Space Systems Command's (SSC) Tactically Responsive Space (TacRS) mission, VICTUS HAZE.

Contracts

RKLB

Rocket Lab Announces The Completion Of Its Critical Design Review For The U.S. Space Force Space Systems Command's Tactically Responsive Space Mission, VICTUS HAZE

INSM

Insmed Announces FDA No Advisory Meeting For Brensocatib NDA In Non-Cystic Fibrosis Bronchiectasis

Oppenheimer analyst Leland Gershell upgrades Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) from Perform to Outperform and announces $98 price target.

Upgrades

BMRN

Oppenheimer Upgrades Biomarin Pharmaceutical to Outperform, Announces $98 Price Target

Lincoln Educational Services Expects To Make Marked Progress Toward Achieving Objectives Of $550M In Revenue And $90M In Adjusted EBITDA In 2027

Small Cap Consumer Research analyst Eric Beder reiterates Vera Bradley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) with a Buy and maintains $5.5 price target.

Reiteration

Small Cap Consumer Research Reiterates Buy on Vera Bradley, Maintains $5.5 Price Target

<ul>
<li>Quest to provide comprehensive dialysis-related laboratory and water testing services to&nbsp;Fresenius Medical Care owned and affiliated clinics in the United States</li>
</ul>
BAD HOMBURG, Germany and SECAUCUS, N.J., Feb. 24, 2025 /PRNewswire/ --&nbsp;Fresenius Medical Care ((XETRA: FME, NYSE:<a href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>), the world's leading provider of products and services for individuals with renal disease, and Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>), a leading provider of diagnostic information services, today announced that, under terms of a definitive acquisition agreement, Quest will acquire select assets of FME's wholly owned Spectra Laboratories, a leading&nbsp; provider of renal-specific laboratory testing services in the U.S. &nbsp;
In addition, under a separate agreement, Quest will provide comprehensive laboratory services related to end-stage kidney disease (ESKD) and specialized water testing for patients and providers served by dialysis centers operated by Fresenius Medical Care and its wholly owned and joint-venture partners in the United States.

Quest Diagnostics Acquires Select Assets Of Fresenius's Spectra Laboratories For Dialysis Testing Services In U.S., Terms Not Disclosed

ANIX

Anixa Biosciences Announces CAR-T Therapy For Ovarian Cancer, Developed With Moffitt Cancer Center

Press Releases

Revolution Medicines to Participate in Upcoming Investor Conferences

Earnings

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

Revolution Medicines Announces Commencement of Public Offering of Common Stock

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Comments

Revolution Medicines

ニュース

パートナーシップ

ベンジンガ・グローバル